Marginally failed study for Europe [Study As­sess­ment]

posted by balakotu – India, 2018-04-24 07:30 (1278 d 20:46 ago) – Posting: # 18726
Views: 3,432

I have conducted a full replicate BE study for one of the highly variable product for Europe regulatory.
Based on the reference product variability, relaxed 90% Confidence Intervals is 75.18 to 133.01 for Cmax.
Study marginally failed with 90% upper CI data of 133.18
Is there any way to justify Europe regulatory authority(ies) to accept this study data? (DCP submission)


Edit: Category changed; see also this post #1 and #4. [Helmut]

Complete thread:

 Admin contact
21,753 posts in 4,548 threads, 1,544 registered users;
online 2 (0 registered, 2 guests [including 2 identified bots]).
Forum time: Sunday 04:17 CEST (Europe/Vienna)

They were “so intent of making everything numerical”
that they frequently missed seeing
what was there to be seen.    Barbara McClintock

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz